Version June 2024
| Organization | Age to initiate (years)¶ | Age to discontinue (years) | Recommended screening test and frequency | Post-hysterectomy (with cervix removed) for benign disease | HPV vaccination | |
| In our practice, we use the following guidelines, in order of preference: | ||||||
| USPSTF (2018) | 21 | 65Δ | Age 21 to 29 years Pap test every 3 years | Age ≥30 years One of these methods:
| Not indicated§ | Same recommendations as unvaccinated patients |
| ACS (2020) | 25 | 65¥ | Age ≥25 years One of these methods:
| Not indicated‡ | Same recommendations as unvaccinated patients | |
| Other expert group recommendations: | ||||||
| Age 21 to 29 years | Age ≥30 years | |||||
| ACOG (2021) | 21 | 65Δ | Pap test every 3 years | One of these methods:
| Not indicated§ | Same recommendations as unvaccinated patients |
| ACP (2015) | 21 | 65Δ | Pap test every 3 years | One of these methods:
| Not indicated§ | N/A |
| ASCCP/SGO (2015 interim guidelines) | 21 | N/A | Can consider primary HPV testing◊ every 3 years for patients age ≥25 | Can consider primary HPV testing◊ every 3 years | N/A | N/A |
| ACS/ASCCP/ASCP (2012) | 21¶ | 65† | Pap test every 3 years (preferred) | One of these methods:
| Not indicated** | Same recommendations as unvaccinated patients |
HPV: human papillomavirus; ACS: American Cancer Society; ASCCP: American Society for Colposcopy and Cervical Pathology; ASCP: American Society for Clinical Pathology; SGO: Society of Gynecologic Oncology; USPSTF: United States Preventive Services Task Force; ACOG: American College of Obstetricians and Gynecologists; ACP: American College of Physicians; DES: diethylstilbestrol; HIV: human immunodeficiency virus; CIN: cervical intraepithelial neoplasia; FDA: US Food and Drug Administration.
* These guidelines are intended for the general population and are not intended for patients with a history of cervical cancer, high-grade cervical precancers, DES in utero exposure, or who are immunocompromised (eg, HIV infection).
¶ Regardless of the age of initiation of sexual activity.
Δ For patients with no history of CIN 2 or higher with evidence of prior adequate screening (3 or more negative cytology test results in a row or 2 consecutive negative co-tests in the past 10 years, with the most recent within the past 5 years).
◊ Only certain HPV tests are approved by the FDA for primary HPV testing (ie, Cobas, BD Onclarity).
§ For patients who have had a benign hysterectomy with removal of the cervix who do not have a history of CIN 2 or higher.
¥ For patients with evidence of adequate negative prior screening (2 consecutive negative primary HPV tests or co-tests within the past 10 years, with the most recent test within the previous 5 years, or 3 consecutive negative Pap tests within the past 10 years, with the most recent test within the previous 3 years) and no history of CIN 2 or greater within the last 25 years. Screening should not be resumed for any reason, even if a woman has a new sexual partner.
‡ For patients who have had a benign hysterectomy with removal of the cervix who do not have a history of CIN 2 or 3 in the past 25 years, or a history of cervical cancer ever.
† For patients with evidence of adequate negative prior screening (consecutive negative cytology results or 2 consecutive negative co-tests within the previous 10 years, with the most recent test within the previous 5 years) and no history of CIN 2 or greater within the last 20 years. Screening should not be resumed for any reason, even if the patient has a new sexual partner.
** For patients who have had a benign hysterectomy with removal of the cervix who do not have a history of CIN 2, CIN 3 in the past 20 years, or a history of cervical cancer ever.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
